Ads
related to: hereditary angioedema
Search results
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
Zacks via Yahoo Finance Canada· 1 month agoIntellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I...
Gene-editing offers hope for people with potentially fatal hereditary disorder
PA Media: Science via Yahoo Canada News· 5 months agoA breakthrough gene therapy could offer hope to people with a potentially fatal hereditary...
Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug
Zacks via Yahoo Finance Canada· 12 months agoAstria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is...
KalVista (KALV) Surges 15% on Update From Angioedema Study
Zacks via Yahoo Finance Canada· 12 months agoKalVista (KALV) announces a positive update from its late-stage study on its lead product candidate,...
KalVista ends trials of angioedema drug
Reuters via Yahoo Finance Canada· 2 years agoOct 4 (Reuters) - KalVista Pharmaceuticals Inc said on Tuesday it has terminated a mid-stage study for its drug to prevent recurrent swelling attacks in people with hereditary angioedema, due ...
KalVista shares sink after ending drug trial for hereditary disease
Reuters via Yahoo Canada News· 2 years agoThe drug developer cited increased levels of liver enzymes in some patients, which could lead to liver damage if kept unchecked, for the termination. "The current formulation will not meet our ...
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Zacks via Yahoo Finance Canada· 1 week agoThe FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance Canada· 2 months agoIntellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript May 9, 2024 Intellia...
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
Zacks via Yahoo Finance Canada· 2 months agoIntellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company...
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Zacks via Yahoo Finance Canada· 2 months agoIonis Pharmaceuticals IONS reported a loss of 98 cents per share for first-quarter 2024, which was...
